Agios Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $50.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar has given his Buy rating due to a combination of factors that balance competitive pressure with Agios’ remaining strengths. She acknowledges that Novo Nordisk’s etavopivat generated more compelling sickle cell disease data than Agios’ mitapivat, particularly on vaso-occlusive crises, and that this likely limits mitapivat’s ultimate market share. Even so, she still expects mitapivat to secure U.S. approval for sickle cell disease, supported by a solid hemoglobin response profile and recent FDA feedback enabling an accelerated filing.
Emily also highlights that mitapivat could reach the market slightly ahead of etavopivat and will benefit from Agios’ existing commercial infrastructure and physician relationships in hematology, which should help the franchise gain an initial foothold. She factors in Novo’s strong competitive positioning and lowers her price target to reflect a reduced opportunity in sickle cell disease, but continues to see meaningful value in Agios’ pipeline and the revenue potential of mitapivat across indications, supporting the continuation of a Buy rating on the shares.
Bodnar covers the Healthcare sector, focusing on stocks such as Agios Pharma, NovoCure, and Agenus. According to TipRanks, Bodnar has an average return of 10.4% and a 38.96% success rate on recommended stocks.
In another report released today, Truist Financial also maintained a Buy rating on the stock with a $39.00 price target.